Metabolomics profiling predicts outcome of tocilizumab in rheumatoid arthritis: an exploratory study.

ABSTRACT:

Introduction

To study metabolic signatures can be used to identify predictive biomarkers for a patient's therapeutic response.

Objectives

We hypothesized that the characterization of a patients' metabolic profile, utilizing one-dimensional nuclear magnetic resonance (¹H-NMR), may predict a response to tocilizumab in patients with rheumatoid arthritis (RA).

Methods

40 active RA patients meeting the 2010 ACR/EULAR classification criteria initiating treatment with tocilizumab were recruited. Clinical outcomes were determined at baseline, and after six and twelve months of treatment. EULAR response criteria at 6 and 12 months to categorize patients as responders and non-responders. Blood was collected at baseline and after six months of tocilizumab therapy.

SUBMITTER: Murillo-Saich JD 

PROVIDER: S-EPMC8810395 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature